Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
28 juin 2022 07h00 HE
|
Revolution Medicines, Inc.
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise,...
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
09 juin 2022 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
09 mai 2022 16h02 HE
|
Revolution Medicines, Inc.
Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination...
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
21 avr. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
09 mars 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
01 mars 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
28 févr. 2022 16h05 HE
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
22 févr. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
03 févr. 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
11 janv. 2022 14h15 HE
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers First Patient Dosed in Global Phase...